Arrowhead Pharmaceuticals vs Ultragenyx Pharmaceutical
Arrowhead Pharmaceuticals is the larger business, with $829m of revenue in fiscal 2025 against $673m for Ultragenyx Pharmaceutical (1.2 times as much). Arrowhead Pharmaceuticals grew faster (23258.2% against 20.2%). Arrowhead Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -0.2% against -85.4%.
| Latest fiscal year | Arrowhead PharmaceuticalsARWR, 2025 | Ultragenyx PharmaceuticalRARE, 2025 |
|---|---|---|
| Revenue | $829m | $673m |
| Revenue growth | 23258.2% | 20.2% |
| Net income | −$1.6m | −$575m |
| Operating margin | — | -79.5% |
| Net margin | -0.2% | -85.4% |
| Return on equity | -0.5% | — |
| Free cash flow | $157m | −$472m |
| Cash | $227m | $421m |
| Total debt | $255m | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 711 | 1,371 |
| Market value | $8.43bn | $1.65bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 64 sales | 0 buys, 28 sales |